Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety Study of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Cutaneous Cancer

This study has been completed.
Sponsor:
Information provided by:
PCI Biotech AS
ClinicalTrials.gov Identifier:
NCT00993512
First received: October 9, 2009
Last updated: June 17, 2011
Last verified: October 2009
  Purpose

This study is an open, non- randomized, phase I, dose-escalating study to evaluate the safety and tolerance of Amphinex based PCI of bleomycin in patients with local recurrent or advanced/metastatic, cutaneous or sub-cutaneous malignancies.


Condition Intervention Phase
Head and Neck Neoplasms
Skin Neoplasms
Drug: Amphinex (TPCS2a)
Drug: Bleomycin
Other: Illumination with CeramOptec laser
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I, Dose-escalating Study to Evaluate Safety and Tolerance of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Local Recurrence or Advanced/Metastatic, Cutaneous or Sub-cutaneous Malignancies

Resource links provided by NLM:


Further study details as provided by PCI Biotech AS:

Primary Outcome Measures:
  • Dose limiting toxicity [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Tumour response according to Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Enrollment: 19
Study Start Date: August 2009
Study Completion Date: May 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TPCS2a
No comparative treatment is given in this open-label phase I, dose escalating safety study
Drug: Amphinex (TPCS2a)
intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
Other Name: Amphinex
Drug: Bleomycin
intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
Other: Illumination with CeramOptec laser
intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.

Detailed Description:

Eligible patients will be included in cohorts of 3 patients. The initial starting dose for Amphinex will be given 4 days prior to the fixed dose of bleomycin administered by intravenous infusion. The illumination, with red light (laser 652 nm), to the tumour surface and a margin of 2-3 mm outside the tumour surface, will be performed after bleomycin administration.

There will be no comparative procedure in this study. Dose escalation will proceed according to a modification of Simon's accelerated titration design. The number of patients recruited depends on the DLT experienced. A total of 6 patients will be included at each dose level if no more than 1 patient experiences DLT.

Additional cohorts may be added pending the outcome of the previous cohorts and discussions between the investigators and the Sponsor. The primary goal of the study is to assess the safety and tolerance of the Amphinex and determine the maximal tolerated dose (MTD) of Amphinex as a PCI therapy in combination with bleomycin treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female aged 18 years or above who have given written informed consent.
  • Skin type I- IV according to the Fitzpatrick skin classification (see appendix G).
  • With a diagnosis of local recurrence or advanced/metastatic, cutaneous or subcutaneous malignancy
  • Lesion measurement must not be done more than 2 weeks before the beginning of treatment. More than one field with lesion can be illuminated, but care must be taken to avoid overlap of the fields illuminated.
  • Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, anticancer hormone therapy, or other investigational therapy for at least 2 weeks prior to study entry, and have recovered from the acute effects of therapy.
  • Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Scale (see appendix D).
  • Clinically assessed as eligible for bleomycin chemotherapy.
  • Have a predicted life expectancy of at least 3 months.
  • Geographic proximity that allow adequate follow-up.
  • If female: have had childbearing potential either terminated by surgery, radiation, or menopause or attenuated by the use of an approved contraceptive method during and for 3 months after the trial.
  • If male: have had reproductive potential either terminated or attenuated by the use of an approved contraceptive method during and for 3 months after the trial.

Exclusion Criteria:

  • Have received prior PCI.
  • Tumours known to be eroding into a major blood vessel in or adjacent to the illumination site.
  • Planned surgery in first 28 days after treatment, except for planned surgical removal of the treated lesion.
  • Planned dentist appointments in first 28 days after treatment.
  • Anticancer therapy within the first 28 days after treatment.
  • Therapy with drugs that induce light sensitivity (e.g. tetracyclines, sulfonamides, phenothiazines, sulfonylurea, hypoglycemic agents, thiazide diuretics, and griseofulvin) within the first 14 days after treatment.
  • Co-existing ophthalmic disease likely to require slit-lamp examination within the first 28 days after treatment.
  • History of hypersensitivity/anaphylactic reactions.
  • Previous cumulative dose of Bleomycin received over 200 000 IE
  • Known allergy or sensitivity to photosensitisers.
  • Known allergy to Cremophor.
  • Known allergy to bleomycin.
  • Conditions contraindicated for bleomycin treatment (lung infection, impaired pulmonary function).
  • Conditions that worsen when exposed to light (including porphyria).
  • Conditions associated with a risk of poor protocol compliance.
  • Pregnancy or breastfeeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00993512

Locations
United Kingdom
University College London Hospital
London, United Kingdom, NW1 2PG
Sponsors and Collaborators
PCI Biotech AS
Investigators
Principal Investigator: Colin Hopper, MD University College London Hospitals
  More Information

No publications provided

Responsible Party: Anders Høgset, Research Director, PCI Biotech AS
ClinicalTrials.gov Identifier: NCT00993512     History of Changes
Other Study ID Numbers: PCI 101/06
Study First Received: October 9, 2009
Last Updated: June 17, 2011
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by PCI Biotech AS:
photochemical internalisation
photosensitiser
cutaneous tumour
sub-cutaneous tumour
dose escalation

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms
Skin Neoplasms
Neoplasms by Site
Skin Diseases
Bleomycin
Antibiotics, Antineoplastic
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014